Published Data Show Why GSK Bailed on Its Maternal RSV Vaccine
(MedPage Today) -- GSK's abandoned maternal respiratory syncytial virus (RSV) vaccine protected infants from severe RSV, final results of a phase III trial indicated, but those positive outcomes came at the expense of an unexplained higher risk... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 14, 2024 Category: Infectious Diseases Source Type: news
Risk for Preterm Birth Stops Maternal RSV Vaccine Trial Risk for Preterm Birth Stops Maternal RSV Vaccine Trial
With a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 14, 2024 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
Prevention and Impact of Respiratory Syncytial Virus Prevention and Impact of Respiratory Syncytial Virus
Almost 10,000 older adults die each year due to respiratory syncytial virus. Two new FDA-approved RSV vaccines may help lower that number, and also ease congestion in hospitals.Medscape (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - March 13, 2024 Category: Infectious Diseases Tags: Infectious Diseases Commentary Source Type: news
Vaccine delivery initiative expands in Sierra Leone
A medical care and vaccine delivery project, co-led by Yale ’s Mushfiq Mobarak, is expanding into remote, rural parts of the West African nation. (Source: Yale Science and Health News)
Source: Yale Science and Health News - March 13, 2024 Category: Universities & Medical Training Source Type: news
COVID-19 Vaccination Linked to Lower Risk for Postinfection Outcomes
WEDNESDAY, March 13, 2024 -- COVID-19 vaccination is associated with a reduced risk for post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection cardiac and thromboembolic outcomes, according to a study published online March 12... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2024 Category: Pharmaceuticals Source Type: news
Flu vaccination programme moved to October to ‘maximise’ protection
The flu vaccination programme in England has been moved from September to October this year in order to maximise vaccine effectiveness. Based on advice from the Joint Committee on Vaccination and Immunisation (JCVI), the government has asked GP practices to deliver most flu vaccines from October, with an exact start date to be confirmed by... Read moreThe post Flu vaccination programme moved to October to ‘maximise’ protection appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - March 13, 2024 Category: Nursing Authors: Megan Ford Tags: Clinical Latest news Vaccinations and infections Source Type: news
Zimbabwe: Zimbabwe Surpasses 4 Million Polio Vaccination Target
[263Chat] The Ministry of Health and Child Care (MOHCC) in collaboration with UNICEF, the World Health Organization (WHO), Bill and Melinda Gates Foundation (BMGF), US Centre for Disease Control (USCDC) and other partners have surpassed the four million target for polio vaccination using the nOPV2 vaccine. (Source: AllAfrica News: Polio)
Source: AllAfrica News: Polio - March 13, 2024 Category: Infectious Diseases Tags: Health and Medicine Polio Southern Africa Zimbabwe Source Type: news
Nigeria: 1 Million Children in Nigeria Die Every Year From Diseases - - Minister
[Vanguard] The Coordinating Minister of Health and Social Welfare, Prof. Ali Muhammad Pate, said 1 million children under five years old die every year in Nigeria from diseases, including vaccine-preventable ailments. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 13, 2024 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news
European Commission approves Pfizer & #039;s PREVENAR 20 ® to help protect infants and children against pneumococcal disease
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. (Source: World Pharma News)
Source: World Pharma News - March 13, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Decoding Variants and Virology With Professor Marc Van Ranst Decoding Variants and Virology With Professor Marc Van Ranst
Learn from Prof Van Ranst about SARS-CoV-2 with insights on varied immune effects, systemic implications, evolving variants, and their influence on vaccination and healthcare practices.Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 13, 2024 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news
Sentences of note
COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes. These effects were more pronounced for acute COVID-19 outcomes, consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection. Here is the full article…#núriamercadébesora #singaporean (Source: Reuters: Health)
Source: Reuters: Health - March 13, 2024 Category: Consumer Health News Source Type: news
Merck to Test Single-dose Regimen Of HPV Vaccine Gardasil 9 Merck to Test Single-dose Regimen Of HPV Vaccine Gardasil 9
Merck& Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 13, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Africa: What's Behind the Worldwide Shortage of Cholera Vaccines? for Starters, They're Only Made By One Company
[The Conversation Africa] In February 2024 the World Health Organization announced southern Africa was suffering the deadliest regional outbreak of cholera in at least a decade. At the epicentre of the disaster were Malawi, Zimbabwe and Mozambique, where cholera cases surged more than four-fold between 2022 and 2023. Over 1,600 deaths were reported in the three countries. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 13, 2024 Category: African Health Tags: Africa External Relations Health and Medicine International Organizations and Africa Malawi Mozambique Southern Africa Zimbabwe Source Type: news
Covid vaccines cut risk of virus-related heart failure and blood clots, study finds
Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complicationsCovid vaccinations substantially reduce the risk of heart failure and potentially dangerous blood clots linked to the infection for up to a year, according to a large study.Researchers analysed health records from more than 20 million people across the UK, Spain and Estonia and found consistent evidence that the jabs protected against serious cardiovascular complications of the disease.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 12, 2024 Category: Science Authors: Ian Sample Science editor Tags: Medical research Coronavirus Science Health Vaccines and immunisation World news Infectious diseases Society Source Type: news
The UK could be a vaccine superpower, but it needs a booster
We risk forgetting the lessons of the Covid pandemic (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - March 12, 2024 Category: Pharmaceuticals Source Type: news
